E3810

DRUG4 trials

Sponsors

Eisai Co., Ltd., Eisai Inc.

Conditions

Gastric or Duodenal Ulcers Caused by Low-dose AspirinHealthyNon-erosive Gastroesophageal Reflux DiseaseRefractory Reflux Esophagitis

Phase 1

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

CompletedNCT01153659

Eisai Inc.Healthy

Start: 2010-07-31End: 2010-10-31Updated: 2013-11-01

Phase 2

Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis

CompletedNCT00770913

Eisai Co., Ltd.Refractory Reflux Esophagitis

Start: 2008-10-31End: 2010-03-31Updated: 2012-04-18

Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

CompletedNCT01397448

Eisai Co., Ltd.Gastric or Duodenal Ulcers Caused by Low-dose Aspirin

Start: 2011-07-31End: 2013-06-30Updated: 2014-11-26

Phase 3

A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease

CompletedNCT00165646

Eisai Co., Ltd.Non-erosive Gastroesophageal Reflux Disease

Start: 2004-09-30End: 2005-10-31Updated: 2011-07-18